<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04598399</url>
  </required_header>
  <id_info>
    <org_study_id>PHRCN/2018/AL-01</org_study_id>
    <nct_id>NCT04598399</nct_id>
  </id_info>
  <brief_title>Comparison of the Effectiveness of Two Psycho-physical Interventions: Mindfulness Based Relapse Prevention (MBRP) and Unguided Meditative Relaxation in Patients With Alcohol Use Disorder</brief_title>
  <acronym>MBRP</acronym>
  <official_title>Comparison of the Effectiveness of Two Psycho-physical Interventions: Mindfulness Based Relapse Prevention (MBRP) and Unguided Meditative Relaxation in Patients With Alcohol Use Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Nīmes</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Nīmes</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Alcohol use disorder (AUD) is the second highest preventable cause of death in France. Only&#xD;
      3% of patients are prescribed approved drugs for reducing alcohol consumption or maintenance&#xD;
      of abstinence. Increasing evidence supports the efficacy of psychotherapies such as cognitive&#xD;
      and behavioral therapies (CBT) in AUD. However, some patients are resistant to CBT and the&#xD;
      positive effects of CBT could wane over time, resulting in mid- and long-term relapses.&#xD;
      Mindfulness practice is increasingly widespread in the United States and its efficacy in&#xD;
      various fields appears very promising. The study investigators hypothesize that the&#xD;
      Mindfulness Based Relapse Prevention (MBRP) program will be more efficient than a&#xD;
      relaxation/meditation without guidance control program in AUD.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 2021</start_date>
  <completion_date type="Anticipated">November 2025</completion_date>
  <primary_completion_date type="Anticipated">April 2025</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>In order to limit measurement and attrition biases, the patient will be kept unaware of the hypotheses concerning the details of the evaluated programs (MBRP or control) and the program expected to be superior</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction in number of heavy drinking days (HDD) over previous 4 weeks, between the last drinking period at inclusion and 6 months.</measure>
    <time_frame>6 months</time_frame>
    <description>Alcohol Time Line Follow Back (TLFB) where a HDD = consummation of 4+ (for women) or 5+ (for men) drinks per day.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in number of heavy drinking days (HDD) during the last 4 weeks, between the last drinking period at inclusion and 3 months between groups</measure>
    <time_frame>3 months</time_frame>
    <description>Alcohol Time Line Follow Back (TLFB) where a HDD = consummation of 4+ (for women) or 5+ (for men) drinks per day.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in number of heavy drinking days (HDD) during the last 4 weeks, between the last drinking period at inclusion and 12 months between groups</measure>
    <time_frame>12 months</time_frame>
    <description>Alcohol Time Line Follow Back (TLFB) where a HDD = consummation of 4+ (for women) or 5+ (for men) drinks per day.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in 4-week total alcohol consumption since baseline</measure>
    <time_frame>3 months</time_frame>
    <description>number of drinks (1 glass = 1 unit according to grams alcohol)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in 4-week total alcohol consumption since baseline</measure>
    <time_frame>12 months</time_frame>
    <description>number of drinks (1 glass = 1 unit according to grams alcohol)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in frequency of craving since baseline</measure>
    <time_frame>3 months</time_frame>
    <description>version F of craving experience questionnaire (CEQ-F)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in frequency of craving since baseline</measure>
    <time_frame>6 months</time_frame>
    <description>version F of craving experience questionnaire (CEQ-F)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in frequency of craving since baseline</measure>
    <time_frame>12 months</time_frame>
    <description>version F of craving experience questionnaire (CEQ-F)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in strength of craving since baseline</measure>
    <time_frame>3 months</time_frame>
    <description>version S of craving experience questionnaire (CEQ-S)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in strength of craving since baseline</measure>
    <time_frame>6 months</time_frame>
    <description>version S of craving experience questionnaire (CEQ-S)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in strength of craving since baseline</measure>
    <time_frame>12 months</time_frame>
    <description>version S of craving experience questionnaire (CEQ-S)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anxiety at baseline</measure>
    <time_frame>Baseline</time_frame>
    <description>Beck Anxiety Inventory depression (BAI): 21-item self-assessment scale assessing anxiety</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in anxiety since baseline</measure>
    <time_frame>3 months</time_frame>
    <description>Beck Anxiety Inventory depression (BAI): 21-item self-assessment scale assessing anxiety</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in anxiety since baseline</measure>
    <time_frame>6 months</time_frame>
    <description>Beck Anxiety Inventory depression (BAI): 21-item self-assessment scale assessing anxiety</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in anxiety since baseline</measure>
    <time_frame>12 months</time_frame>
    <description>Beck Anxiety Inventory depression (BAI): 21-item self-assessment scale assessing anxiety</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Depression at baseline</measure>
    <time_frame>Baseline</time_frame>
    <description>Beck Depression Inventory (BDI): 21 items assessing the presence and severity of depressive symptoms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in depression since baseline</measure>
    <time_frame>3 months</time_frame>
    <description>Beck Depression Inventory (BDI): 21 items assessing the presence and severity of depressive symptoms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in depression since baseline</measure>
    <time_frame>6 months</time_frame>
    <description>Beck Depression Inventory (BDI): 21 items assessing the presence and severity of depressive symptoms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in depression since baseline</measure>
    <time_frame>12 months</time_frame>
    <description>Beck Depression Inventory (BDI): 21 items assessing the presence and severity of depressive symptoms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in quality of life since baseline</measure>
    <time_frame>3 months</time_frame>
    <description>Alcohol Quality of Life Scale (AQoLS): 34-item patient-reported questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in quality of life since baseline</measure>
    <time_frame>6 months</time_frame>
    <description>Alcohol Quality of Life Scale (AQoLS): 34-item patient-reported questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in quality of life since baseline</measure>
    <time_frame>12 months</time_frame>
    <description>Alcohol Quality of Life Scale (AQoLS): 34-item patient-reported questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Emotion regulation at baseline</measure>
    <time_frame>Baseline</time_frame>
    <description>Emotion Regulation Questionnaire (ERQ): 10-item scale designed to assessing Cognitive Reappraisal and Expressive Suppression on a 7-point Likert-type scale ranging from 1 (strongly disagree) to 7 (strongly agree).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in emotion regulation since baseline</measure>
    <time_frame>3 months</time_frame>
    <description>Emotion Regulation Questionnaire (ERQ): 10-item scale designed to assessing Cognitive Reappraisal and Expressive Suppression on a 7-point Likert-type scale ranging from 1 (strongly disagree) to 7 (strongly agree).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in emotion regulation since baseline</measure>
    <time_frame>6 months</time_frame>
    <description>Emotion Regulation Questionnaire (ERQ): 10-item scale designed to assessing Cognitive Reappraisal and Expressive Suppression on a 7-point Likert-type scale ranging from 1 (strongly disagree) to 7 (strongly agree).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in emotion regulation since baseline</measure>
    <time_frame>12 months</time_frame>
    <description>Emotion Regulation Questionnaire (ERQ): 10-item scale designed to assessing Cognitive Reappraisal and Expressive Suppression on a 7-point Likert-type scale ranging from 1 (strongly disagree) to 7 (strongly agree).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difficulties regulating emotion at baseline</measure>
    <time_frame>Baseline</time_frame>
    <description>Difficulties in Emotion Regulation scale (DERS -Impulse): items 3, 14, 19, 24R, 27, 32 from DERS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in difficulties regulating emotion since baseline</measure>
    <time_frame>3 months</time_frame>
    <description>Difficulties in Emotion Regulation scale (DERS -Impulse): items 3, 14, 19, 24R, 27, 32 from DERS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in difficulties regulating emotion since baseline</measure>
    <time_frame>6 months</time_frame>
    <description>Difficulties in Emotion Regulation scale (DERS -Impulse): items 3, 14, 19, 24R, 27, 32 from DERS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in difficulties regulating emotion since baseline</measure>
    <time_frame>12 months</time_frame>
    <description>Difficulties in Emotion Regulation scale (DERS -Impulse): items 3, 14, 19, 24R, 27, 32 from DERS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in impulsivity since baseline</measure>
    <time_frame>3 months</time_frame>
    <description>Impulsive behavior scale (UPPS-P): 20-item self-assessment scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impulsivity at baseline</measure>
    <time_frame>Baseline</time_frame>
    <description>Impulsive behavior scale (UPPS-P): 20-item self-assessment scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in impulsivity since baseline</measure>
    <time_frame>6 months</time_frame>
    <description>Impulsive behavior scale (UPPS-P): 20-item self-assessment scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in impulsivity since baseline</measure>
    <time_frame>12 months</time_frame>
    <description>Impulsive behavior scale (UPPS-P): 20-item self-assessment scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in coping mechanism</measure>
    <time_frame>3 months</time_frame>
    <description>brief COPE questionnaire: 14 scales including 2 items (28 items in total)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Coping mechanism at baseline</measure>
    <time_frame>Baseline</time_frame>
    <description>brief COPE questionnaire: 14 scales including 2 items (28 items in total)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in coping mechanism</measure>
    <time_frame>6 months</time_frame>
    <description>brief COPE questionnaire: 14 scales including 2 items (28 items in total)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in coping mechanism</measure>
    <time_frame>12 months</time_frame>
    <description>brief COPE questionnaire: 14 scales including 2 items (28 items in total)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cognitive impairment</measure>
    <time_frame>Baseline</time_frame>
    <description>Montreal Cognitive Assessment (MoCA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Initial mindfulness</measure>
    <time_frame>Baseline</time_frame>
    <description>Five Facets Mindfulness Questionnaire (FFMQ): 39-item self-assessment tool measuring 5 factors of mindfulness</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of meditation sessions per week over the last 4 weeks</measure>
    <time_frame>Month 6</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">168</enrollment>
  <condition>Alcohol Use Disorder (AUD)</condition>
  <arm_group>
    <arm_group_label>MBRP program:</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard care</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Mindfulness Based Relapse Prevention</intervention_name>
    <description>7 x 60-120 minute sessions with different themes: Automatic pilot/triggers/relapse/high-risk situations/ mindfulness in daily life. There will be a welcoming time, with a focus on at-home practice and difficulties, a theoretical presentation of new concepts, practical meditation exercises and a debriefing.</description>
    <arm_group_label>MBRP program:</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Relaxation/ meditation</intervention_name>
    <description>7 x 60-120 minute sessions each with a different sound from nature with unguided, closed relaxation group with a maximum of 12 participants</description>
    <arm_group_label>Standard care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Having a moderate to severe alcohol use disorder according to DSM 5 criteria.&#xD;
&#xD;
          -  The last drink must have been consumed at most in the last 30 days before the&#xD;
             pre-inclusion visit. The patient must have had at least 1 HDD during the last drinking&#xD;
             period&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Severe depression (Beck Depression Inventory&gt; 30)&#xD;
&#xD;
          -  Schizophrenic disorder,&#xD;
&#xD;
          -  Current maniac or hypomaniac episode,&#xD;
&#xD;
          -  Patient with dementia or severe cognitive impairment that would prevent him/her from&#xD;
             following the course of a session, as judged by the clinician.&#xD;
&#xD;
          -  Insufficient French understanding to complete the questionnaires&#xD;
&#xD;
          -  Pregnant or breastfeeding woman&#xD;
&#xD;
          -  Absence of social security regimen&#xD;
&#xD;
          -  Other mindfulness-based structured therapies&#xD;
&#xD;
          -  Refusal to sign the written consent. • The patient is under safeguard of justice or&#xD;
             state guardianship&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Amandine Luquiens</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Nimes</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Amandine Luquiens</last_name>
    <phone>04.66.68.69.98</phone>
    <email>Amandine.luquiens@chu-nimes.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hôpital Corentin-Celton</name>
      <address>
        <city>Issy-les-Moulineaux</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Patrice Louvillle</last_name>
      <phone>01 58 00 44 25</phone>
      <email>patrice.louvillle@aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Patrice Louvillle</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Nantes</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Marie Grall-Bronnec</last_name>
      <phone>02.40.84.61.16</phone>
      <email>marie.bronnec@chu-nantes.fr</email>
    </contact>
    <investigator>
      <last_name>Marie Grall-Bronnec</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Nimes</name>
      <address>
        <city>Nîmes</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Anissa Megzari</last_name>
      <phone>04.66.68.42.36</phone>
      <email>drc@chu-nimes.fr</email>
    </contact>
    <investigator>
      <last_name>Amandine Luquiens</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinique Des Epinettes</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Marion Groppi</last_name>
      <phone>01 84 82 42 42</phone>
      <email>m.groppi@cliniquedesepinettes.com</email>
    </contact>
    <investigator>
      <last_name>Marion Groppi</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Arnaud Plat</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital Pitié-Salpétriere</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Yves Edel</last_name>
      <phone>01 45 59 69 78</phone>
      <email>yves.edel@aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Yves Edel</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Le CSAPA - Association Charonne</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Pascale Bouthillon-Heizmann</last_name>
      <phone>01 45 83 22 22</phone>
      <email>pascale.bouthillon@charonne.asso.fr</email>
    </contact>
    <investigator>
      <last_name>Pascale Bouthillon-Heizmann</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital Paul Brousse</name>
      <address>
        <city>Villejuif</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Amine Benyamina</last_name>
      <phone>01 45 59 69 78</phone>
      <email>secretariat.addictologie.pbr@aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Amine Benyamina</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>October 16, 2020</study_first_submitted>
  <study_first_submitted_qc>October 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 22, 2020</study_first_posted>
  <last_update_submitted>August 4, 2021</last_update_submitted>
  <last_update_submitted_qc>August 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alcoholism</mesh_term>
    <mesh_term>Alcohol Drinking</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

